This major finding highlights the potential of ALKBH5 as a therapeutic target in the treatment of GBM radioresistance since inhibiting this RNA demethylase can block multiple partners of the homologous recombination, including the key players of this pathway, RAD51 and CHK1. The gene discussed is RAD51; the disease is glioblastoma.